#Israel #Tel Aviv #Lutris Pharma #LUT014 #ESMO Congress

Lutris Pharma to Present Phase 2 Trial Data at ESMO 2025

Lutris Pharma, a clinical-stage biopharmaceutical company, is preparing to present findings from its Phase 2 trial of LUT014 gel at the upcoming European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress, scheduled for July 2-5, 2025, in Barcelona, Spain. This event will highlight the innovative efforts in developing treatments that enhance the effectiveness of anti-cancer therapies while addressing undesirable side effects.

Understanding LUT014 and Its Clinical Importance

LUT014 is a groundbreaking topical B-Raf inhibitor designed to provide relief from the adverse dermatological reactions—specifically, acneiform rash—that often afflict patients undergoing treatment with epidermal growth factor receptor (EGFR) inhibitors. These inhibitors are crucial in modern cancer therapies but frequently result in side effects that diminish patients' quality of life and can hinder their adherence to treatment plans.

In a rigorous double-blind, placebo-controlled randomized trial, Lutris Pharma evaluated the efficacy of LUT014 in patients suffering from skin rashes as a direct result of their cancer therapy. Notably, this innovative approach represents a significant step forward in managing the dermatological challenges associated with EGFR inhibitors, thereby improving patient outcomes.

Details of the Clinical Trial Presentation

The presentation at ESMO will be led by Dr. Ofer Purim, a distinguished figure in the field and the Head of the Gastrointestinal Malignancy Unit at the Helmsley Cancer Center. His team’s research underscores the importance of mitigating the cutaneous side effects that frequently accompany the use of EGFR inhibitors.

• - Presentation Title: A double-blind placebo-controlled randomized phase 2 clinical trial to assess the efficacy of a topical BRAF inhibitor for acneiform rash toxicities from anti-EGFR therapies.
• - Session Date: Friday, July 4, 2025
• - Time: 5:30 – 5:40 PM CET
• - Location: Madrid Room

The Challenge of EGFR Inhibitor-Induced Skin Reactions

The epidermal growth factor receptor (EGFR) is critical in controlling various cellular activities, including growth and survival. The drugs targeting EGFR are lauded for their effectiveness against numerous cancers, yet they come with a range of unfortunate side effects, such as the papulopustular rash that may resemble acne. This condition not only inflicts physical discomfort but also significantly impacts patients' emotional and psychological states.

The novel mechanism of LUT014 exploits the paradoxical actions of B-Raf inhibition, emphasizing its potential to counteract the undesirable skin responses while maintaining efficacy in cancer treatment. By enhancing cell proliferation in non-mutated tissues, LUT014 strives to reconcile the delicate balance between reducing harmful effects and supporting necessary treatment processes.

Lutris Pharma’s Commitment to Patient Relief

Lutris Pharma is committed to pioneering topical solutions that help patients endure the hardships associated with cancer therapies. With LUT014 leading the way, the company aims to alleviate the burdens of skin toxicity, thereby facilitating better compliance to critical therapies—an objective that remains at the forefront of Lutris Pharma’s mission.

The recent successful completion of the Phase 2 trial for LUT014 among colorectal cancer patients suffering from acneiform lesions is a testament to the ongoing commitment of Lutris Pharma to enhance cancer care and overall patient wellbeing.

For more information about Lutris Pharma and its innovative therapeutic solutions, visit www.lutris-pharma.com.

Lutris Pharma continues to pave the way towards a future where cancer patients can undergo their necessary treatments with greater comfort and improved quality of life.